About Contact Us Careers

Preimplantation Genetic Testing Market Size and Forecast, by Technology (Next-Generation Sequencing, Polymerase Chain Reaction); Application (HLA Typing, Aneuploidy Screening, IVF Prognosis); Procedure Type (Preimplantation Genetic Diagnosis, Preimplantation Genetic Screening); Products & Services (Instruments, Reagents & Consumables, Software & Services) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 4793
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Preimplantation Genetic Testing Market Outlook:

Preimplantation Genetic Testing Market size was valued at USD 858.88 million in 2025 and is likely to cross USD 2.07 billion by 2035, expanding at more than 9.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of preimplantation genetic testing is assessed at USD 930 million.

Preimplantation Genetic Testing Market
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The growth of the preimplantation genetic testing market can be attributed to the rise in the number of new births born with congenital genetic disorders. The embryo is examined for a wide range of genetic problems during preimplantation genetic testing. According to the Centers for Disease Control and Prevention, the most frequent chromosomal disorder identified in the US is still Down syndrome. In the United States, roughly 6,000 newborns are born with Down syndrome every year. This indicates that roughly 1 in 700 infants have Down syndrome.

In addition to these, factors that are believed to fuel the preimplantation genetic testing market growth of preimplantation genetic testing include the rising cases of failed pregnancies, miscarriages, and others. Preimplantation genetic testing is typically utilized when women want to examine their embryos for issues that could result in another unsuccessful treatment after experiencing many miscarriages or failed IVF cycles. Embryos can also be examined for chromosomal issues using this method. Besides this, another application of preimplantation genetic testing, such as pre-implantation tissue typing is also helpful in testing for various blood disorders, including Wiscott-Aldrich Syndrome, and Sickle Cell Anaemia. PTT ensures the safe birth of a baby without any disease, moreover, it also predicts if the older sibling can successfully be treated with the stem cells of the new infant.

Key Preimplantation Genetic Testing Market Insights Summary:

  • Regional Highlights:

    • North America preimplantation genetic testing market is predicted to capture 38% share by 2035, driven by rising infertility cases and increasing need for bone marrow and organ transplants.
    • Europe market will account for 25% share by 2035, driven by rising neonatal deaths and congenital genetic deformities boosting IVF demand.

  • Segment Insights:

    • The hla typing segment in the preimplantation genetic testing market is expected to achieve significant share by 2035, fueled by rising demand for organ transplantation and bone marrow.
    • The preimplantation genetic diagnosis segment in the preimplantation genetic testing market will hold the largest share, driven by its high efficiency over the forecast period 2026-2035.

  • Key Growth Trends:

    • Growing Cases of Neo-Natal Deaths
    • Rising Prevalence of Congenital Genetic Diseases

  • Major Challenges:

    • Lack of Skilled Researchers and Physicians
    • Public Companies are Subjected to Strict Judicial Rules

  • Key Players: Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., PerkinElmer LSDX, Abbott, Natera, Inc., Yikon Genomics, Invitae Corporation, Genea Energy Partners Inc., Eurofins Genoma Germany GmbH, Genomic Prediction.

Global Preimplantation Genetic Testing Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 858.88 million
    • 2026 Market Size: USD 930 million
    • Projected Market Size: USD 2.07 billion by 2035
    • Growth Forecasts: 9.2% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (38% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Japan, Germany, United Kingdom
    • Emerging Countries: China, India, Japan, South Korea, Malaysia

    • Last updated on : 10 September, 2025

Growth Drivers

  • Growing Cases of Neo-Natal Deaths - Many neo-natal deaths are associated with the genetic deformity. Therefore, it is likely to boost market growth. According to the UNICEF, worldwide, 6,400 newborn deaths occurred per day in 2021, totaling 2.3 million infant deaths in the first month of life. Also, in 2021, there were an average of 18 deaths per 1,000 live births worldwide, making the first month of life the most dangerous for children.
  • Rising Prevalence of Congenital Genetic Diseases - Preimplantation genetic diagnosis enables early detection of faulty chromosomes and helps in preventing congenital genetic deformity in unborn babies. According to the World Health Organization, every year, congenital diseases are considered to be the root cause of 240 000 newborn deaths globally that occur within 28 days of birth. An additional 170 000 children under the age of five die from congenital diseases each year.
  • Rise in the Number of Women at a Reproductive Age - Preimplantation genetic testing is used for checking chromizing during pregnancy, therefore increasing share of women at reproductive age is expected to increase the pregnancy cases and consequently the use genetic testing. According to the most recent expenditure data, global health spending has grown over the past 20 years, doubling in real terms to reach USD 8.5 trillion in 2019 and 9.8% of GDP, up from 8.5 percent in 2000. It is predicted that this boom would continue over the forecast period.
  • Growing Use of In-Vitro Fertilization - Preimplantation genetic testing (PGT) checks embryos created by in vitro fertilization (IVF) for a variety of genetic issues that could result in implantation failure, miscarriage, and birth abnormalities in the offspring. According to recent projections, nearly 400 million people, or approximately 3% of the global population, may be living by the year 2100 as a result of IVF and other fertility procedures.
  • Number of People Living with Genetic Disorders - Monogenic preimplantation genetic testing is used to check for a particular genetic pathogenic variant linked to a family history of a certain disease. In the world, around 5000–8000 rare diseases have been identified, affecting up to 6–8% of the population. An estimated 40% of uncommon disorders are caused by genetic factors.

Challenges

  • Moral Stigma Associated with the Treatment- Few people also recognize preimplantation genetic testing as morally repugnant owing to its intention to create and destroy human embryos in an unnatural manner. There have been orthodox beliefs attached to it, involvement of the treatment interferes with god’s natural creation and everything should not be altered with the interference of science. This element is also anticipated to limit preimplantation genetic testing market expansion.
  • Lack of Skilled Researchers and Physicians
  • Public Companies are Subjected to Strict Judicial Rules

Preimplantation Genetic Testing Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

9.2%

Base Year Market Size (2025)

USD 858.88 million

Forecast Year Market Size (2035)

USD 2.07 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Preimplantation Genetic Testing Market Segmentation:

Procedure Type Segment Analysis       

The global is segmented and analyzed for demand and supply by procedure type into preimplantation genetic diagnosis, and preimplantation genetic screening. Out of the types of procedures, the preimplantation genetic diagnosis segment is estimated to gain the largest preimplantation genetic testing market share in the year 2035. The growth of the segment can be attributed to the high efficiency of preimplantation genetic diagnosis. For high-genetic-risk couples with a known genetic condition, preimplantation genetic diagnosis (PGD) has been utilized successfully. Moreover, couples now have the chance to learn crucial genetic details about their embryos before starting a pregnancy owing to this revolutionary reproductive method.  The hemoglobin illnesses thalassemia and sickle cell, the Fragile X syndrome, mental impairment condition, and muscular dystrophies are a few examples of single gene disorders for which couples frequently choose to use PGD. Preimplantation genetic diagnosis (PGD), also known as PGT-M, can be performed in conjunction with IVF to screen for more than 600 uncommon genetic disorders, including Cystic Fibrosis and premature Alzheimer's.

Application Segment Analysis       

The global preimplantation genetic testing market is also segmented and analyzed for demand and supply by application into HLA typing, aneuploidy screening, IVF prognosis, and others. Amongst these four applications of preimplantation genetic testing, the HLA typing segment is expected to garner a significant share in the year 2035. HLA typing examines certain immune system-related variables, and examination can determine whether a person is healthy enough to safely donate bone marrow, cord blood, or an organ to someone in need of a transplant. Moreover, organ donors who are terminally sick or recently passed away can also undergo HLA typing. The growth of the segment is primarily attributed to the rising demand for organ transplantation and the growing need for bone marrow. A bone marrow or umbilical cord blood transplant could save around 18,000 people between the ages of 0 and 74 every year, perhaps saving their lives.

Our in-depth analysis of the global preimplantation genetic testing market includes the following segments:

          By Technology
  • Next-Generation Sequencing
  • Polymerase Chain Reaction

         By Application
  • HLA Typing
  • Aneuploidy Screening
  • IVF Prognosis
  • Others

        By Procedure Type
  • Preimplantation Genetic Diagnosis
  • Preimplantation Genetic Screening

        By Products & Services
  • Instruments
  • Reagents & Consumables
  • Software & Services

         By End User
  • Hospitals
  • Maternity Centers & Fertility Clinics
  • Diagnostic Labs
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Preimplantation Genetic Testing Market Regional Analysis:

North American Market Insights

The market share of preimplantation genetic testing in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 38% by the end of 2035. The growth of the market can be attributed majorly to the rising cases of infertility in the region. According to Statistics Canada, in 2023, Canada's fertility rate is expected to be around 1.484 births per woman, a nearly 0.54% decrease from 2022. In Canada, the fertility rate fell by around 0.53% from 2021 to 2022, to around 1.492 births per woman. On the other hand, market growth in the region is also expected on the account of the rising need for bone marrow transplantation and organ transplantation. In the United States in 2020, more than 23,000 bone marrow or umbilical cord blood transplants were carried out.

Europe Market Insights

The European preimplantation genetic testing market is estimated to be the second largest, registering a share of about 25% by the end of 2035. The growth of the market can be attributed majorly to the rising frequency of neo natal deaths. According to the Eurostat, in the EU, there were approximately 14 100 infant deaths in 2019. This translates to 3.4 newborn deaths for every 1000 live births, or the infant mortality rate. In addition to this, growing cases of congenital genetic deformity are also anticipated to boost the market growth in Europe. In the EU, there were approximately 14 100 infant deaths in 2019. This translates to 3.4 newborn deaths for every 1000 live births, or the infant mortality rate. Moreover, in Europe, the average age of first-time motherhood is also increasing which in turn pushing people to go for in-vitro fertilization in order to conceive.

APAC Market Insights

Asia Pacific region is projected to observe substantial growth through 2035. The growth of the market can be attributed majorly to the increasing instances of stem cells, organ, and bone marrow transplants. Any sort of transplantation has become safer with the use of preimplantation genetic testing, that ensures if the donor is healthy enough to donate and if receiver is getting the donation from its perfect match. Around 2,000 stem cell transplants are performed in India each year, 80,000 to 1,00,000 transplants are needed each year to address the high incidence of blood malignancies and severe blood diseases. However, finding a compatible donor is quite challenging. Moreover, less than a million Indian bone marrow donors are listed on the registry.

Preimplantation Genetic Testing Market Size
Get Strategic Analysis by Region Now: Request Free Sample PDF

Preimplantation Genetic Testing Market Players:

    • Illumina, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • PerkinElmer LSDX
    • Abbott
    • Natera, Inc.
    • Yikon Genomics
    • Invitae Corporation
    • Genea Energy Partners Inc.
    • Eurofins Genoma Germany GmbH
    • Genomic Prediction

Recent Developments

  • Eurofins Genoma launched niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. Preimplantation genetic testing for aneuploidy (PGT-A) enables medical professionals to determine the chromosomal makeup of in vitro fertilized (IVF) embryos

  • LifeView powered by Genomic Prediction announces the partnership of Ovation Fertility with Genomic Prediction to approve the license for the LIfeView PGT Platform for genetic testing. Through this partnership, Ovation patients will have access to cutting-edge technologies and better clinical care.

  • Report ID: 4793
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of preimplantation genetic testing is assessed at USD 930 million.

The global preimplantation genetic testing market size was valued at over USD 858.88 million in 2025 and is expected to expand at a CAGR of more than 9.2%, surpassing USD 2.07 billion revenue by 2035.

North America preimplantation genetic testing market is predicted to capture 38% share by 2035, driven by rising infertility cases and increasing need for bone marrow and organ transplants.

Key players in the market include Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., PerkinElmer LSDX, Abbott, Natera, Inc., Yikon Genomics, Invitae Corporation, Genea Energy Partners Inc., Eurofins Genoma Germany GmbH, Genomic Prediction.

Preimplantation Genetic Testing Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos